

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



13th October 2017

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

Dear Sir/Madam,

Sub: Investor Grievances Report for the quarter ended 30th September, 2017
Ref: Reg. 13(3) of SEBI (LODR) Regulations, 2015


We refer to the above captioned subject, we herewith submit you the report on investor grievances for the quarter ended 30th September, 2017 as required under Reg. 13(3) of SEBI (LODR) Regulations, 2015.

Particulars	Complaints pending at the beginning of the period ended 30-06-2017	Complaints received during the period ended 30-09-2017	Complaints disposed and resolved at the end of the quarter	Complaints unresolved at the end of the quarter
Non-receipt of Share certificates	1	0	0	1
Non-receipt of duplicate share certificates	0	0	0	0
Non-receipt of Annual Report	0	0	0	0
Transmission of Securities	0	0	0	0
Non-receipt of dividend Warrants	0	0	0	0
Complaints registered in SCORES/Stock Exchanges	1	0	0	1
Total	2	0	0	2

Kindly note that the complaint pertaining to non-receipt of share certificate and complaint registered with Stock Exchange is filed by same shareholder.
Kindly take the same into your records.

Thanking you

Yours Faithfully
For Krebs Biochemicals & Industries Limited


Haritha Varanasi
Company Secretary